Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

Low dose cyclophosphamide: Mechanisms of T cell modulation

(2016) Mutsa Tatenda Madondo et al.   CANCER TREATMENT REVIEWS

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2016) Floris Dammeijer et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic Melanoma – A Review of Current and Future Treatment Options

(2015) E Maverakis et al.   ACTA DERMATO-VENEREOLOGICA

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

(2015) Saskia J. A. M. Santegoets et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Postoperative Regulatory T-Cells and Natural Killer Cells in Stage I Nonsmall Cell Lung Cancer Underwent Video-assisted Thoracoscopic Lobectomy or Thoracotomy

(2015) Gang Chen et al.   CHINESE MEDICAL JOURNAL

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

(2015) Koji Kurose et al.   Journal of Thoracic Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

(2015) Dass S. Vinay et al.   SEMINARS IN CANCER BIOLOGY

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

(2015) Michal Podrazil et al.   Oncotarget

Nivolumab in melanoma: latest evidence and clinical potential

(2015) Douglas B. Johnson et al.   Therapeutic Advances in Medical Oncology

Nivolumab in NSCLC: latest evidence and clinical potential

(2015) Raghav Sundar et al.   Therapeutic Advances in Medical Oncology

Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic

(2015) Franck Housseau et al.   OncoImmunology

Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model

(2014) Junjie Wu et al.   CANCER LETTERS

Immunomodulation in cancer

(2014) Joost PJJ Hegmans et al.   CURRENT OPINION IN PHARMACOLOGY

Malignant Pleural Mesothelioma

(2013) Andrew R. Haas et al.   CLINICS IN CHEST MEDICINE

Changes of CD4+CD25+FOXP3+ and CD8+CD28− regulatory T cells in non-small cell lung cancer patients undergoing surgery

(2013) Cheng Chen et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response

(2013) Daniel Heylmann et al.   PLoS One

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

(2013) D. Sugiyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

(2013) Mark J. Dobrzanski   Frontiers in Oncology

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

(2012) Melanie J. McCoy et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Optimal Population of FoxP3+ T Cells in Tumors Requires an Antigen Priming-Dependent Trafficking Receptor Switch

(2012) Chuanwu Wang et al.   PLoS One

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

(2011) Yingzi Ge et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

(2011) Tom Treasure et al.   LANCET ONCOLOGY

Malignant Pleural Mesothelioma

(2011) Siva Raja et al.   Current Oncology Reports

Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma

(2010) Joost P. Hegmans et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity

(2010) Joris D. Veltman et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Different Proliferative Potential and Migratory Characteristics of Human CD4+ Regulatory T Cells That Express either CD45RA or CD45RO

(2010) N. J. Booth et al.   JOURNAL OF IMMUNOLOGY

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low-dose IL-2

(2010) J. Bjoern et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor

(2009) Makoto Miyara et al.   IMMUNITY